207 related articles for article (PubMed ID: 11204292)
1. Relation of left ventricular geometry and function to systemic hemodynamics in hypertension: the LIFE Study. Losartan Intervention For Endpoint Reduction in Hypertension Study.
Bella JN; Wachtell K; Palmieri V; Liebson PR; Gerdts E; Ylitalo A; Koren MJ; Pedersen OL; Rokkedal J; Dahlöf B; Roman MJ; Devereux RB
J Hypertens; 2001 Jan; 19(1):127-34. PubMed ID: 11204292
[TBL] [Abstract][Full Text] [Related]
2. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension.
Devereux RB; Roman MJ; Palmieri V; Okin PM; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Wachtell K; Dahlöf B
J Hypertens; 2000 Aug; 18(8):1129-38. PubMed ID: 10954006
[TBL] [Abstract][Full Text] [Related]
3. Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study.
Devereux RB; Palmieri V; Liu JE; Wachtell K; Bella JN; Boman K; Gerdts E; Nieminen MS; Papademetriou V; Dahlöf B
J Hypertens; 2002 Jul; 20(7):1445-50. PubMed ID: 12131543
[TBL] [Abstract][Full Text] [Related]
4. Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study.
Wachtell K; Dahlöf B; Rokkedal J; Papademetriou V; Nieminen MS; Smith G; Gerdts E; Boman K; Bella JN; Devereux RB
Am Heart J; 2002 Dec; 144(6):1057-64. PubMed ID: 12486431
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular function and hemodynamic features of inappropriate left ventricular hypertrophy in patients with systemic hypertension: the LIFE study.
Palmieri V; Wachtell K; Gerdts E; Bella JN; Papademetriou V; Tuxen C; Nieminen MS; Dahlöf B; de Simone G; Devereux RB
Am Heart J; 2001 May; 141(5):784-91. PubMed ID: 11320367
[TBL] [Abstract][Full Text] [Related]
6. Left ventricular filling patterns in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study). Losartan Intervention For Endpoint.
Wachtell K; Smith G; Gerdts E; Dahlöf B; Nieminen MS; Papademetriou V; Bella JN; Ibsen H; Rokkedal J; Devereux RB
Am J Cardiol; 2000 Feb; 85(4):466-72. PubMed ID: 10728952
[TBL] [Abstract][Full Text] [Related]
7. Systolic left ventricular function according to left ventricular concentricity and dilatation in hypertensive patients: the Losartan Intervention For Endpoint reduction in hypertension study.
Bang CN; Gerdts E; Aurigemma GP; Boman K; Dahlöf B; Roman MJ; Køber L; Wachtell K; Devereux RB
J Hypertens; 2013 Oct; 31(10):2060-8. PubMed ID: 23838656
[TBL] [Abstract][Full Text] [Related]
8. Effect of electrocardiographic left ventricular hypertrophy on left ventricular systolic function in systemic hypertension (The LIFE Study). Losartan Intervention For Endpoint.
Wachtell K; Rokkedal J; Bella JN; Aalto T; Dahlöf B; Smith G; Roman MJ; Ibsen H; Aurigemma GP; Devereux RB
Am J Cardiol; 2001 Jan; 87(1):54-60. PubMed ID: 11137834
[TBL] [Abstract][Full Text] [Related]
9. Relationship between electrocardiographic voltage and geometric patterns of left ventricular hypertrophy in patients with essential hypertension.
Tomita S; Ueno H; Takata M; Yasumoto K; Tomoda F; Inoue H
Hypertens Res; 1998 Dec; 21(4):259-66. PubMed ID: 9877519
[TBL] [Abstract][Full Text] [Related]
10. Endogenous ouabain and hemodynamic and left ventricular geometric patterns in essential hypertension.
Pierdomenico SD; Bucci A; Manunta P; Rivera R; Ferrandi M; Hamlyn JM; Lapenna D; Cuccurullo F; Mezzetti A
Am J Hypertens; 2001 Jan; 14(1):44-50. PubMed ID: 11206678
[TBL] [Abstract][Full Text] [Related]
11. Impact of left ventricular geometry on prognosis in hypertensive patients with left ventricular hypertrophy (the LIFE study).
Gerdts E; Cramariuc D; de Simone G; Wachtell K; Dahlöf B; Devereux RB
Eur J Echocardiogr; 2008 Nov; 9(6):809-15. PubMed ID: 18490279
[TBL] [Abstract][Full Text] [Related]
12. Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
Wachtell K; Palmieri V; Olsen MH; Bella JN; Aalto T; Dahlöf B; Gerdts E; Wright JT; Papademetriou V; Mogensen CE; Borch-Johnsen K; Ibsen H; Devereux RB
Am Heart J; 2002 Feb; 143(2):319-26. PubMed ID: 11835038
[TBL] [Abstract][Full Text] [Related]
13. Modified Cornell electrocardiographic criteria in the assessment of left ventricular hypertrophy geometry of patients with essential hypertension.
Xu M; Ge Z; Huang J; Shao X; Li J; Mrcp ; Yang J
J Clin Hypertens (Greenwich); 2020 Jul; 22(7):1239-1246. PubMed ID: 32639109
[TBL] [Abstract][Full Text] [Related]
14. Relation of ambulatory blood pressure load with left ventricular geometry in untreated patients with mild-to-moderate hypertension.
Tsioufis C; Stefanadis C; Goumas G; Pitsavos C; Toutouzas P
J Hum Hypertens; 1999 Oct; 13(10):677-82. PubMed ID: 10516737
[TBL] [Abstract][Full Text] [Related]
15. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.
Muscholl MW; Schunkert H; Muders F; Elsner D; Kuch B; Hense HW; Riegger GA
Am Heart J; 1998 Jan; 135(1):58-66. PubMed ID: 9453522
[TBL] [Abstract][Full Text] [Related]
16. Four-group classification of left ventricular hypertrophy based on ventricular concentricity and dilatation identifies a low-risk subset of eccentric hypertrophy in hypertensive patients.
Bang CN; Gerdts E; Aurigemma GP; Boman K; de Simone G; Dahlöf B; Køber L; Wachtell K; Devereux RB
Circ Cardiovasc Imaging; 2014 May; 7(3):422-9. PubMed ID: 24723582
[TBL] [Abstract][Full Text] [Related]
17. Relation of hemodynamics and risk factors to ventricular-vascular interactions in the elderly: the Cardiovascular Health Study.
de Simone G; McClelland R; Gottdiener JS; Celentano A; Kronmal RA; Gardin JM
J Hypertens; 2001 Oct; 19(10):1893-903. PubMed ID: 11593112
[TBL] [Abstract][Full Text] [Related]
18. Changes and significance of subtype function of beta-adrenoreceptors in left ventricular remodeling of hypertension.
Yingxin P; Jiang S; Xiaoyong Q; Hao X; Chunli R; Dongmei Y; Zhiqin G; Shiling Z; Min W
Jpn Heart J; 2003 Nov; 44(6):933-42. PubMed ID: 14711188
[TBL] [Abstract][Full Text] [Related]
19. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension.
Ganau A; Devereux RB; Roman MJ; de Simone G; Pickering TG; Saba PS; Vargiu P; Simongini I; Laragh JH
J Am Coll Cardiol; 1992 Jun; 19(7):1550-8. PubMed ID: 1534335
[TBL] [Abstract][Full Text] [Related]
20. Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
Palmieri V; Okin PM; de Simone G; Bella JN; Wachtell K; Gerdts E; Boman K; Nieminen MS; Dahlöf B; Devereux RB
J Hypertens; 2007 May; 25(5):1079-85. PubMed ID: 17414673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
